Latest Lymphocytic Leukemia Stories
SAN FRANCISCO, Dec.
U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.
WHITE PLAINS, N.Y., Dec.
Filing completed less than two months after first European approval for IMBRUVICA® SUNNYVALE, Calif., Dec. 1, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
SEATTLE, Nov. 18, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc.
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
LONDON and SUNNYVALE, Calif., Nov. 4, 2014 /PRNewswire/ -- AstraZeneca and Pharmacyclics, Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).